© Sudok1 | Dreamstime.com A trial at Oxford University suggests an existing low cost drug can cut the risk of death from Covid-19 substantially. Tests involving 6,000 hospitalised Covid-19 patients suggest the drug can cut the risk of death for those on ventilators from 40% to 28%. For patients needing oxygen the risk of death ...
Topics:
Investec considers the following as important: 3) Swiss Markets and News, 3.) Health, Coronavirus Switzerland, Covid-19 Switzerland, Editor's Choice, Featured, health, newsletter, SARS-CoV-2 Switzerland, Science and technology
This could be interesting, too:
Investec writes Swiss inflation falls further in January
Investec writes Catching ski pass cheats – reactions, fines and worse
RIA Team writes The Importance of Emergency Funds in Retirement Planning
Nachrichten Ticker - www.finanzen.ch writes Gesetzesvorschlag in Arizona: Wird Bitcoin bald zur Staatsreserve?

© Sudok1 | Dreamstime.com
A trial at Oxford University suggests an existing low cost drug can cut the risk of death from Covid-19 substantially.
Tests involving 6,000 hospitalised Covid-19 patients suggest the drug can cut the risk of death for those on ventilators from 40% to 28%. For patients needing oxygen the risk of death could be cut from 25% to 20%.
The findings are potentially the biggest breakthrough in Covid-19 treatment so far. Lead researcher Prof Martin Landray told the BBC that the findings suggested one life could be saved for every eight patients on a ventilator and one for every 20-25 treated with oxygen.
The drug, dexamethasone, is a steroid treatment that calms the immune response. A course of the globally available drug costs around £35.
However, the drug does not seem to help those with milder symptoms who do not need help breathing.
Tags: Coronavirus Switzerland,Covid-19 Switzerland,Editor's Choice,Featured,Health,newsletter,SARS-CoV-2 Switzerland,Science and technology